These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35949208)

  • 1. suPAR: An Inflammatory Mediator for Kidneys.
    Sudhini YR; Wei C; Reiser J
    Kidney Dis (Basel); 2022 Jul; 8(4):265-274. PubMed ID: 35949208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
    Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
    Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
    Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
    J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
    Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
    Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
    Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
    Outinen TK; Mäkelä S; Huttunen R; Mäenpää N; Libraty D; Vaheri A; Mustonen J; Aittoniemi J
    J Intern Med; 2014 Oct; 276(4):387-95. PubMed ID: 24717117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
    Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
    Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Formyl Peptide Receptors and β-Arrestin-1 in suPAR Signal Transduction in Mouse Podocytes: Interactions with αVβ3-Integrin.
    Kim EY; Dryer SE
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective.
    Benucci M; Damiani A; Russo E; Guiducci S; Li Gobbi F; Fusi P; Grossi V; Amedei A; Manfredi M; Infantino M
    J Pers Med; 2022 Dec; 12(12):. PubMed ID: 36556207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ; Deegens JK; Wetzels JF
    Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases.
    Manfredi M; Van Hoovels L; Benucci M; De Luca R; Coccia C; Bernardini P; Russo E; Amedei A; Guiducci S; Grossi V; Bossuyt X; Perricone C; Infantino M
    J Pers Med; 2023 Apr; 13(4):. PubMed ID: 37109074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. suPAR and chronic kidney disease-a podocyte story.
    Zeier M; Reiser J
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
    Jo M; Thomas KS; Wu L; Gonias SL
    J Biol Chem; 2003 Nov; 278(47):46692-8. PubMed ID: 12963722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?
    Saleem MA
    Nephron; 2018; 139(4):334-341. PubMed ID: 29909410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.